Catalent

More from Catalent

Catalent New Acquisition

Catalent Acquires Erytech Facility in New Jersey

The company has paid $44.5 million for commercial-scale cell therapy development and manufacturing facility, and has entered into an exclusive, long-term supply agreement to support Erytech’s lead product candidate.

Catalent Shanghai

Catalent Increasing Temperature-controlled Clinical Supply Capabilities

The company will be expanding its Waigaoqiao Free Trade Zone facility in Shanghai, China, to increase capacity for temperature-controlled storage and distribution of clinical supplies, as well as additional secondary packaging capabilities.

Catalent’s OptiDose Design Solution uses a design approach, combining data-driven scientific tools with development expertise.

Catalent: Dose Form Decision Platform

Catalent launches its OptiDose Design Solution to help create differentiated treatments that are successful for innovators, patients, and health care professionals.

Catalent's Bloomington, IN, facility became its base of operations to fight against the pandemic.

OEM Collaboration Against the Spread of COVID

Optima Pharma, Herma, and Rondo-Pak streamline efforts to provide needed machinery in the time-sensitive production of vaccines.

With time of the essence, Rondo-Pak employees produced a quarter of a million complicated cartons in a week and a half, by hand.

Catalent Incorporates High Speed Cartoning for Vaccine Packaging

In the race to package COVID-19 vaccines, Rondo-Pak hand-assembled hundreds of thousands of cartons with partitions, exact replicas of the cartons Dividella cartoner would soon be producing for Catalent.

Efficiency-minded modules offer optimization-minded features such as innovative rotary tables, digital position indicators and format sets that can be changed without tools for fast format changes.

HERMA US Supplies High-volume Wraparound Labeling Machines for Biologic Production, COVID-19 Vaccines

HERMA US delivers two HERMA 132M HC wrap-around labelers in just 10 weeks.

The partnership will include the provision and accelerated delivery of advanced visual inspection systems to help with potential solutions to the pandemic.

Partnership to Expedite Installation of Automated Inspection Equipment

Stevanato Group high-speed visual inspection machines will support biologic and vaccine programs at Catalent manufacturing sites in the US and Italy.

Catalent Signs Agreement with AstraZeneca to Manufacture COVID-19 Vaccine Candidate

The agreement accelerates the rapid scale-up of capacity over the coming months to support the dedicated production of AZD1222.

Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy

Bristol-Myers Squibb will maintain strategic presence in Italy through ongoing development and commercialization of new medicines. Catalent will continue to manufacture products for Bristol-Myers Squibb while offering other customers access to state-of-the-art sterile biologics fill/finish and oral solids manufacturing and packaging platforms